<?xml version="1.0" encoding="UTF-8"?>
<p>A human na√Øve plasma was obtained from a healthy volunteer in Germany. The MAYV plasma was obtained from a patient who had contracted MAYV, presenting with fever, myalgia, maculopapular rash, and polyarthralgias whilst travelling in Bolivia [
 <xref rid="B30-viruses-11-00082" ref-type="bibr">30</xref>]. CHIKV antibody positive plasma samples were obtained from Puerto Rican blood donors as well as from Brazilian patients that had been clinically diagnosed with and later tested for ZIKV, DENV or CHIKV infections. Plasma samples were obtained from Brazilian patients followed at the Viral Hepatitis Ambulatory/FIOCRUZ/Rio de Janeiro following IRB approval of study amendments. The approval date was May 10, 2016 (Fiocruz IRB ID: 0142/01). RRV or BFV plasma samples were obtained from Australian blood donors and screened for the presence of RRV or Barmah Forest virus (BFV) IgG and/or IGM, following approval from the Australian Red Cross Blood Service Human Research Ethics committee. Samples labeled CHIKV (
 <xref ref-type="fig" rid="viruses-11-00082-f003">Figure 3</xref>, 
 <xref ref-type="fig" rid="viruses-11-00082-f004">Figure 4</xref> and 
 <xref ref-type="fig" rid="viruses-11-00082-f005">Figure 5</xref>) were always the same sample of a Puerto Rican donor.
</p>
